The Prognostic Impact of the Metastatic Lymph Nodes Ratio in Colorectal Cancer

Chi-Hao Zhang, Yan-Yan Li, Qing-Wei Zhang, Alberto Biondi, Valeria Fico, Roberto Persiani, Xiao-Chun Ni, Meng Luo

Research output: Contribution to journalArticle

Abstract

Background: This study was designed to validate the prognostic significance of the ratio of positive to examined lymph nodes (LNR) in patients with colorectal cancer. Methods: 218,314 patients from the SEER database and 1,811 patients from the three independent multicenter were included in this study. The patients were divided into 5 groups on a basis of previous published LNR: LNR0, patients with no metastatic lymph nodes; LNR1, patients with the LNR between 0.1 and 0.17; LNR2, patients with the LNR between 0.18 and 0.41; LNR3, patients with the LNR between 0.42 and 0.69; LNR4, patients with the LNR >0.7. The 5-year OS and CSS rate were estimated using Kaplan-Meier method and the survival difference was tested using log-rank test. Multivariate Cox analysis was used to further assess the influence of the LNR on patients' outcome. Results: The 5-year OS rate of patients within LNR0 to LNR4 group was 71.2, 55.8, 39.3, 22.6, and 14.6%, respectively (p < 0.001) in the SEER database. While the 5-year OS rate of those with LNR0 to LNR4 was 75.2, 66.1, 48.0, 34.0, and 17.7%, respectively (p < 0.001) in the international multicenter cohort. In the multivariate analysis, LNR was demonstrated to be a strong prognostic factor in patients with < 12 and ≥12 metastatic lymph nodes. Furthermore, the LNR had a similar impact on the patients' prognosis in colon cancer and rectal cancer. Conclusion: The LNR allowed better prognostic stratification than the positive node (pN) in patients with colorectal cancer and the cut-off values were well validated.

Original languageEnglish
Pages (from-to)628
JournalFrontiers in Oncology
Volume8
DOIs
Publication statusPublished - 2018

Fingerprint

Colorectal Neoplasms
Lymph Nodes
Multivariate Analysis
Databases
Rectal Neoplasms
Colonic Neoplasms

Cite this

The Prognostic Impact of the Metastatic Lymph Nodes Ratio in Colorectal Cancer. / Zhang, Chi-Hao; Li, Yan-Yan; Zhang, Qing-Wei; Biondi, Alberto; Fico, Valeria; Persiani, Roberto; Ni, Xiao-Chun; Luo, Meng.

In: Frontiers in Oncology, Vol. 8, 2018, p. 628.

Research output: Contribution to journalArticle

Zhang, Chi-Hao ; Li, Yan-Yan ; Zhang, Qing-Wei ; Biondi, Alberto ; Fico, Valeria ; Persiani, Roberto ; Ni, Xiao-Chun ; Luo, Meng. / The Prognostic Impact of the Metastatic Lymph Nodes Ratio in Colorectal Cancer. In: Frontiers in Oncology. 2018 ; Vol. 8. pp. 628.
@article{5a22b9268a49493abe425046678cb6c1,
title = "The Prognostic Impact of the Metastatic Lymph Nodes Ratio in Colorectal Cancer",
abstract = "Background: This study was designed to validate the prognostic significance of the ratio of positive to examined lymph nodes (LNR) in patients with colorectal cancer. Methods: 218,314 patients from the SEER database and 1,811 patients from the three independent multicenter were included in this study. The patients were divided into 5 groups on a basis of previous published LNR: LNR0, patients with no metastatic lymph nodes; LNR1, patients with the LNR between 0.1 and 0.17; LNR2, patients with the LNR between 0.18 and 0.41; LNR3, patients with the LNR between 0.42 and 0.69; LNR4, patients with the LNR >0.7. The 5-year OS and CSS rate were estimated using Kaplan-Meier method and the survival difference was tested using log-rank test. Multivariate Cox analysis was used to further assess the influence of the LNR on patients' outcome. Results: The 5-year OS rate of patients within LNR0 to LNR4 group was 71.2, 55.8, 39.3, 22.6, and 14.6{\%}, respectively (p < 0.001) in the SEER database. While the 5-year OS rate of those with LNR0 to LNR4 was 75.2, 66.1, 48.0, 34.0, and 17.7{\%}, respectively (p < 0.001) in the international multicenter cohort. In the multivariate analysis, LNR was demonstrated to be a strong prognostic factor in patients with < 12 and ≥12 metastatic lymph nodes. Furthermore, the LNR had a similar impact on the patients' prognosis in colon cancer and rectal cancer. Conclusion: The LNR allowed better prognostic stratification than the positive node (pN) in patients with colorectal cancer and the cut-off values were well validated.",
author = "Chi-Hao Zhang and Yan-Yan Li and Qing-Wei Zhang and Alberto Biondi and Valeria Fico and Roberto Persiani and Xiao-Chun Ni and Meng Luo",
year = "2018",
doi = "10.3389/fonc.2018.00628",
language = "English",
volume = "8",
pages = "628",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - The Prognostic Impact of the Metastatic Lymph Nodes Ratio in Colorectal Cancer

AU - Zhang, Chi-Hao

AU - Li, Yan-Yan

AU - Zhang, Qing-Wei

AU - Biondi, Alberto

AU - Fico, Valeria

AU - Persiani, Roberto

AU - Ni, Xiao-Chun

AU - Luo, Meng

PY - 2018

Y1 - 2018

N2 - Background: This study was designed to validate the prognostic significance of the ratio of positive to examined lymph nodes (LNR) in patients with colorectal cancer. Methods: 218,314 patients from the SEER database and 1,811 patients from the three independent multicenter were included in this study. The patients were divided into 5 groups on a basis of previous published LNR: LNR0, patients with no metastatic lymph nodes; LNR1, patients with the LNR between 0.1 and 0.17; LNR2, patients with the LNR between 0.18 and 0.41; LNR3, patients with the LNR between 0.42 and 0.69; LNR4, patients with the LNR >0.7. The 5-year OS and CSS rate were estimated using Kaplan-Meier method and the survival difference was tested using log-rank test. Multivariate Cox analysis was used to further assess the influence of the LNR on patients' outcome. Results: The 5-year OS rate of patients within LNR0 to LNR4 group was 71.2, 55.8, 39.3, 22.6, and 14.6%, respectively (p < 0.001) in the SEER database. While the 5-year OS rate of those with LNR0 to LNR4 was 75.2, 66.1, 48.0, 34.0, and 17.7%, respectively (p < 0.001) in the international multicenter cohort. In the multivariate analysis, LNR was demonstrated to be a strong prognostic factor in patients with < 12 and ≥12 metastatic lymph nodes. Furthermore, the LNR had a similar impact on the patients' prognosis in colon cancer and rectal cancer. Conclusion: The LNR allowed better prognostic stratification than the positive node (pN) in patients with colorectal cancer and the cut-off values were well validated.

AB - Background: This study was designed to validate the prognostic significance of the ratio of positive to examined lymph nodes (LNR) in patients with colorectal cancer. Methods: 218,314 patients from the SEER database and 1,811 patients from the three independent multicenter were included in this study. The patients were divided into 5 groups on a basis of previous published LNR: LNR0, patients with no metastatic lymph nodes; LNR1, patients with the LNR between 0.1 and 0.17; LNR2, patients with the LNR between 0.18 and 0.41; LNR3, patients with the LNR between 0.42 and 0.69; LNR4, patients with the LNR >0.7. The 5-year OS and CSS rate were estimated using Kaplan-Meier method and the survival difference was tested using log-rank test. Multivariate Cox analysis was used to further assess the influence of the LNR on patients' outcome. Results: The 5-year OS rate of patients within LNR0 to LNR4 group was 71.2, 55.8, 39.3, 22.6, and 14.6%, respectively (p < 0.001) in the SEER database. While the 5-year OS rate of those with LNR0 to LNR4 was 75.2, 66.1, 48.0, 34.0, and 17.7%, respectively (p < 0.001) in the international multicenter cohort. In the multivariate analysis, LNR was demonstrated to be a strong prognostic factor in patients with < 12 and ≥12 metastatic lymph nodes. Furthermore, the LNR had a similar impact on the patients' prognosis in colon cancer and rectal cancer. Conclusion: The LNR allowed better prognostic stratification than the positive node (pN) in patients with colorectal cancer and the cut-off values were well validated.

U2 - 10.3389/fonc.2018.00628

DO - 10.3389/fonc.2018.00628

M3 - Article

VL - 8

SP - 628

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

ER -